Drug intelligence / Profile preview

Temodex

Development stage
Phase 1
Lead developer
Double Bond Pharmaceutical
Modality
Small Molecules, Hydrogel Systems → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intratumoral, Implant
01

Overview

Temodex is an experimental localized chemotherapy formulation consisting of the alkylating agent temozolomide incorporated into a biodegradable polymer, often described as a hydrogel or powder for gelation. Developed by Grandeur Bio (Shijiazhuang Yuanjia Biotechnology) and originally originating from the Research Institute for Physical and Chemical Problems of the Belarusian State University, it is designed for the treatment of brain cancers, specifically glioblastoma multiforme. The product is intended for application directly into the resection cavity following surgical tumor removal. This approach aims to provide a high local concentration of temozolomide to eliminate residual tumor cells through sustained release, thereby enhancing therapeutic efficacy while minimizing the systemic toxicity typically associated with oral temozolomide administration.

Brand names
Temodex
Other names
Temodexumtemozolomide-loaded polymertemozolomide biodegradable polymer formulation
02

Targets

DNA

Beyond the preview

Go deeper on Temodex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Temodex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call